文献速递心力衰竭与心肌病

转录组与蛋白质组特征识别机械卸载后心衰心肌恢复潜力患者

Distinct Transcriptomic and Proteomic Profile Specifies Patients Who Have Heart Failure With Potential of Myocardial Recovery on Mechanical Unloading and Circulatory Support.
PubMed 文献 · Circulation · 2022-11-30

研究对93例接受LVAD植入的心衰患者(25例应答者、68例非应答者)及12例非衰竭供体心脏行左心室组织全局RNA测序和磷酸肽分析,识别出区分应答者的29个转录本和93个磷酸肽特征,涉及细胞周期调控和细胞外基质/黏着斑两条关键通路。

要点

  • 整合多组学可识别LVAD卸载后心肌恢复潜力患者的分子特征。
  • 应答者与非应答者差异涉及细胞周期调控及细胞外基质/黏着斑通路。
  • 该特征有望指导晚期心衰治疗的患者选择和新靶点发现。

核心结论

  • 首次整合多组学平台刻画非衰竭与衰竭心脏变化,识别定义心肌恢复能力患者的分子指标,可能指导晚期心衰治疗患者选择并发现新治疗靶点。

研究设计与样本

  • 对93例接受LVAD植入的心衰患者(25例应答者、68例非应答者)及12例非衰竭供体心脏的左心室组织行全局RNA测序和磷酸肽谱分析,并通过超声心动图前瞻性监测心肌结构与功能以判定应答者。

主要发现

  • 在非衰竭对照与心衰患者心脏组织间识别出1341个差异调控转录本和288个差异调控磷酸肽。
  • 无偏分子谱识别出29个转录本和93个磷酸肽组成的特征,可区分LVAD卸载后的应答者。
  • 进一步分析突出细胞周期调控和细胞外基质/黏着斑两条关键通路的差异调控。

临床怎么用

  • 该分子特征可用于筛选可能从LVAD卸载后心肌恢复中获益的晚期心衰患者。
  • 细胞周期调控和细胞外基质/黏着斑通路提示潜在心衰治疗新靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Extensive evidence from single-center studies indicates that a subset of patients with chronic advanced heart failure (HF) undergoing left ventricular assist device (LVAD) support show significantly improved heart function and reverse structural remodeling (ie, termed "responders"). Furthermore, we recently published a multicenter prospective study, RESTAGE-HF (Remission from Stage D Heart Failure), demonstrating that LVAD support combined with standard HF medications induced remarkable cardiac structural and functional improvement, leading to high rates of LVAD weaning and excellent long-term outcomes. This intriguing phenomenon provides great translational and clinical promise, although the underlying molecular mechanisms driving this recovery are largely unknown. METHODS: To identify changes in signaling pathways operative in the normal and failing human heart and to molecularly characterize patients who respond favorably to LVAD unloading, we performed global RNA sequencing and phosphopeptide profiling of left ventricular tissue from 93 patients with HF undergoing LVAD implantation (25 responders and 68 nonresponders) and 12 nonfailing donor hearts. Patients were prospectively monitored through echocardiography to characterize their myocardial structure and function and identify responders and nonresponders. RESULTS: These analyses identified 1341 transcripts and 288 phosphopeptides that are differentially regulated in cardiac tissue from nonfailing control samples and patients with HF. In addition, these unbiased molecular profiles identified a unique signature of 29 transcripts and 93 phosphopeptides in patients with HF that distinguished responders after LVAD unloading. Further analyses of these macromolecules highlighted differential regulation in 2 key pathways: cell cycle regulation and extracellular matrix/focal adhesions. CONCLUSIONS: This is the first study to characterize changes in the nonfailing and failing human heart by integrating multiple -omics platforms to identify molecular indices defining patients capable of myocardial recovery. These findings may guide patient selection for advanced HF therapies and identify new HF therapeutic targets.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Drakos, Badolia, Makaju, et al. Distinct Transcriptomic and Proteomic Profile Specifies Patients Who Have Heart Failure With Potential of Myocardial Recovery on Mechanical Unloading and Circulatory Support. Circulation. 2022. PMID: 36448446. doi:10.1161/CIRCULATIONAHA.121.056600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。